C-X-C Motif Chemokine 9
EmergingCXCL9 supports HLH/MAS diagnosis as part of an interferon-gamma-driven inflammatory marker panel, alongside CXCL10 and IL-18.
CXCL9 is very similar to CXCL10 (discussed elsewhere in this set) and is part of the same emerging panel of tests used to recognize a dangerous immune overactivation condition called HLH, especially when combined with a related interleukin marker for extra accuracy.
CXCL9 (MIG) is an interferon-gamma-induced chemokine, closely related to CXCL10, that recruits activated T-cells to sites of inflammation.
As referenced in the HLH discussion earlier, CXCL9 is now included alongside ferritin and soluble CD25 among the inflammatory markers used to support an HLH/macrophage activation syndrome diagnosis in current practice, reflecting the same interferon-gamma-driven pathway as CXCL10.
Measured via serum immunoassay as part of a broader HLH/MAS-suspicious cytokine panel; the IL-18/CXCL9 ratio specifically has been studied as a refinement for improving diagnostic accuracy in distinguishing HLH/MAS from sepsis or other cytokine storm mimics.
Elevated CXCL9, especially in combination with the other markers in this evolving panel (ferritin, soluble CD25, IL-18, CXCL10), supports more confident HLH/MAS diagnosis and can influence the decision to escalate to HLH-directed therapy.
The IL-18/CXCL9 ratio specifically improves diagnostic accuracy for distinguishing HLH/MAS from other causes of cytokine storm.
- General hematology/immunology reference literature on CXCL9 in HLH/MAS diagnostic panels.